​The share of Americans who skipped medical treatment last year because of costs rose substantially, according to a new Federal Reserve survey published in May. The study found that “28% of adults went without some form of medical care in 2022 because they could not afford it, up from 24% in 2021…. The increase in this measure may, in part, reflect consumer responses to inflation as medical care is an area where people can save money by cutting back on spending."

Proactively addressing affordability helps brand teams overcome access challenges during launch, and often increases patient engagement in and utilization of copay and other support programs over the life of the brand. For pharmaceutical manufacturers, affordability must be integrated into their brand strategy from the start.

GoodRx’s latest Yellow Paper provides fresh insights into the affordability gap for branded drugs across a range of specialties, shows how out-of-pocket (OOP) costs impact patient behavior, and offers three strategies you can use to improve communication about affordability options to patients and providers.

Download it now to learn how:

• OOP costs correlate with patient fill rates
• Affordability directly impacts pharmacy pull-through
• Medical specialties have varying gaps between generic and brand OOPs
• To design awareness into your patient support strategy
• To identify and assess strategic external partners

​